United States · Wires & real time · PR Newswire

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

Published by PR Newswire · United States 8 h ago

Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of death ...

Read the full article on PR Newswire Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)

Also worth reading

Business Wire

Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026

Associated Press (Business)

Brazil’s Lula opens state toolbox to woo voters in runoff against Bolsonaro. Here’s what is on offer

Dow Jones Newswires

Dragonfly On-demand Webinar: Middle East: Anticipating a convergence of conflicts

MT Newswires

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

Share

Also worth reading

Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026

Brazil’s Lula opens state toolbox to woo voters in runoff against Bolsonaro. Here’s what is on offer

Dragonfly On-demand Webinar: Middle East: Anticipating a convergence of conflicts

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows